Research Article
Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease
Table 2
The assessment of vascular and metabolic parameters according to the presence of fibrosis.
| | Variables | NAFLD with fibrosis
() | NAFLD without fibrosis
() | Controls
() | |
| | Age (year) | 34.3 ± 6.5 | 33.5 ± 5.5 | 30.8 ± 5.1 | 0.138 | | Smoking (%) | 35 | 39.4 | 22.2 | 0.460 | | BMI (kg/m2) | 29.9 ± 2.8 | 29.1 ± 3.2 | 23.8 ± 2.7 | <0.001 | | WC (cm) | 108 ± 5.6 | 105.4 ± 7.3 | 89 ± 10.1 | <0.001 | | SBP (mmHg) | 131.3 ± 9.9 | 128.3 ± 24.4 | 117.3 ± 8.4 | 0.065 | | DBP (mmHg) | 82 ± 5.9 | 79.3 ± 8.9 | 71.1 ± 5.8 | <0.001 | | FPG (mg/dL) | 100.1 ± 10.3 | 96.3 ± 10.3 | 88.2 ± 6.6 | 0.001 | | 2 h OGTT (mg/dL) | 115.7 ± 30.3 | 100.7 ± 22.7 | 91.1 ± 13.6 | 0.013 | | LDL-C (mg/dL) | 129.2 ± 21.1 | 129.6 ± 35.4 | 106.8 ± 33.3 | 0.059 | | HDL-C (mg/dL) | 38.6 ± 9.3 | 44.6 ± 9.2 | 43.6 ± 10.1 | 0.068 | | Insulin (mU/mL) | 19.1 ± 8.8 | 16.3 ± 10.6 | 10.7 ± 5.5 | 0.028 | | HOMA-IR | 4.8 ± 2.4 | 4 ± 3 | 2.3 ± 1.1 | 0.015 | | hs-CRP (mg/dL) | 3.7 ± 2.2 | 4.4 ± 4.4 | 1.7 ± 1.1 | 0.024 | | PTX3 (ng/mL) | 3.2 ± 2.6 | 1.9 ± 1.2 | 1.7 ± 1.4 | 0.016 | | cf-PWV (m/s) | 8.6 ± 1.3 | 8.2 ± 1.1 | 7.3 ± 1.2 | 0.012 | | CIMT (mm) | 0.485 ± 0.06 | 0.427 ± 0.08 | 0.441 ± 0.07 | 0.028 | | FMD (%) | 11 ± 8 | 11.5 ± 6.3 | 20.1 ± 11.9 | 0.005 |
|
|
NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, WC: waist circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, hs-CRP: high sensitive c reactive protein, FPG: fasting plasma glucose, OGTT: oral glucose tolerance testing, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TG: triglyceride, HOMA-IR: homeostasis model assessment of insulin resistance, PTX3: pentraxin 3, cf-PWV: carotid femoral pulse wave velocity, CIMT: carotid intima media thickness, and FMD: flow mediated dilatation.
|
